

October 15, 2024

CORRECTION NOTICE

Please be advised of corrections made to the English version of our US-approved Pantoprazole availability letter dated October 11, 2024. Please see edits in **red** below.

Pantoprazole for Injection 40 mg SD Vial 10 mL
US-Approved Product – Now Available

Dear Valued Customer,

To help mitigate a drug shortage situation in Canada, Health Canada has permitted the importation and release of **Fresenius Kabi's US-approved Pantoprazole for Injection 40 mg SD Vial 10 mL**.

Healthcare professionals should note that there are differences between the currently approved Canadian product and the product being supplied. Please refer to the following important information:

1. **The Canadian Product Monograph for prescribing information.**
2. **Risk Communication Letter** dated October 11, 2024, describing details and differences between the Canadian– and the US-approved Pantoprazole for Injection products.

The **Risk Communication Letter** and product monograph can be conveniently located on the Fresenius Kabi Canada website at <https://www.fresenius-kabi.com/en-ca/>.

This product will be available to all customers with no restrictions and accessible as of October 16, 2024.

Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Pack Size	Availability Date
433010	980754	193747	Fresenius Kabi's US-approved Pantoprazole for Injection 40 mg SD Vial 10 mL	10	Oct. 16, 2024

If you have any questions or for more information, please contact your Sales Representative or our Customer Service Department at: Canada_CustomerService@Fresenius-Kabi.com or (877) 821-7724.

Sincerely,



Joseph Le
Associate Director, IV Drugs
joseph.le@fresenius-kabi.com

Effective January 1, 2025, we're transitioning to a paperless system and will no longer transmit faxes. Please scan the QR code to sign up for our email communications.

